Optimizerx Corporation ( (OPRX) ) has released its Q3 earnings. Here is a breakdown of the information Optimizerx Corporation presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
OptimizeRx Corporation, headquartered in Waltham, Massachusetts, is a prominent healthcare technology company that specializes in connecting life science brands with patients and healthcare providers through innovative AI-driven tools. The company’s platform facilitates timely and relevant engagement, enhancing healthcare outcomes.
In its latest earnings report, OptimizeRx Corporation announced a significant 22% year-over-year increase in third-quarter revenue, reaching $26.1 million. The company also reported a 30% rise in gross profit, amounting to $17.5 million, and a net income of $0.8 million, marking a turnaround from a loss in the previous year.
Key financial highlights include an increase in non-GAAP net income to $3.9 million and an adjusted EBITDA of $5.1 million, reflecting robust operational performance. The company has also raised its full-year 2025 revenue guidance to a range of $105 million to $109 million and introduced 2026 guidance with expectations of revenue between $118 million and $124 million.
OptimizeRx’s strategic focus on execution and customer outcomes has led to significant contracted revenue gains, positioning the company for continued growth. The company has also made strides in debt reduction, paying off an additional $2 million in principal from its term loan.
Looking ahead, OptimizeRx Corporation remains optimistic about its growth trajectory, with management highlighting strong momentum and visibility into 2026. The company aims to maintain its focus on delivering value to shareholders and advancing its position as a sustainable Rule of 40 company.